How Should We Treat Hyperlipidemia in the Primary Prevention Patient?

Richard M Fleming1*, Matthew R Fleming1 and Tapan K Chaudhuri2

1FHHI-OI-Camelot, Los Angeles, CA, USA
2Department of Radiology, Eastern Virginia Medical School, USA

*Corresponding author: Richard M Fleming, FHHI-OI-Camelot, Los Angeles, CA, USA


Received: December 07, 2019 ; Published: December 20, 2019

Abstract

It is reported that Hippocrates said If someone wishes for good health, one must first ask oneself if he is ready to do away with the reasons for his illness. Only then is it possible to help him and Our food should be our medicine and our medicine should be our food. While we may never know if Hippocrates actually made these statements, they seem intuitively valid. In the later half of the 20th Century, changes in dietary and lifestyle practices raised the awareness of the importance of diet and lifestyle and the development of chronic inflammatory diseases – entering the lexicon [1]– and the understanding that it is this inflammatory process which is ultimately responsible for the development of many of our chronic diseases, including coronary artery disease [2], which has gone on to become the number one killer of people worldwide. This case introduces one such example that should remind us to remain vigilant to what Hippocrates said.

Keywords: Primary prevention; Hyperlipidemia; Statins; Diet; Coronary Artery Calcium (CAC) Score; Cardiac catheterization

Clinical Presentation

A middle age gentleman without known history of prior medical problems underwent routine blood work, revealing an elevated total cholesterol level of 146 mg/dl (3.77 mmol/l). He elected not to begin lipid-lowering medications quoting Hippocrates (above). He stated he planned to change his diet and promised to return in 6-months for repeat blood work. Six months later he returned at which time his total cholesterol was 230 mg/dl (5.95 mmol/l). When he was seen in the clinic, it was discovered that he had been experiencing intermittent chest discomfort. Following recommendations promulgated for decision making in individuals without prior cardiac events and elevated lipids [3], the patient was referred for a coronary artery calcium test (Figure 1), which revealed no evidence of calcium. He was then referred for cardiology evaluation and subsequently underwent cardiac catheterization, revealing a 99% narrowing of his proximal left anterior descending coronary artery (Figure 2-left image) followed by treatment (Figure 2-right image).

Figure 1: Coronary artery calcium study revealed a Calcium Score of zero.
Discussion

In recent years, there has been considerable debate [4-6] over
evidence-based outcomes and the treatment of hyperlipidemia –
particularly in the setting of primary prevention. The fundamental
question being one of How to best approach the patient with
elevated lipids [1] Partially in response to these questions, medical
organizations have attempted to develop evolving guidelines
utilizing changes in diagnostic tools such as coronary artery
calcium (CAC) scores which look for one component of coronary
atherosclerosis –sclerosis – but is truly only a test for calcium
thereby potentially limiting its application [7]. While the time
tested cardiac catheterization – coronary lumenogram also has
its limitations [8-10], like CAC, when positive for the detection of
coronary artery disease (CAD), as it was in this instance, it can
be a life saver particularly when coupled with initial treatment
(stenting), as it was in this case. We emphasize the term initial
treatment because all too often, patients and sometimes their
physicians are under the impression that once a stent is placed,
they no longer have CAD.

The very inflammatory plaque that inflamed and impaired the
coronary artery, eventually invading the coronary lumen, remains
behind after angioplasty (PTCA) or stent placement. As we now
know, the act of PTCA with or without stent placement produces
iatrogenic damage to the wall of the coronary artery through the
outward displacement of the tunica intima, media and externa,
with loss of integrity of the external elastic membrane. A small
price to pay given the alternatives, but nonetheless a consequence,
which should not be ignored or forgotten about. Understanding
the continued nidus for further inflammation [1] is of the utmost
importance in understanding not only how the patient developed
their CAD, but the attention which needs to be given to the
subsequent treatment from here out.

What Would You Do Next?

a) Begin intensive statin regimen followed by frequent lipid
monitoring to maximize treatment and lower lipid levels.

b) Discuss the changes in the dietary patterns followed by
the patient during the 6-month period of time leading up to the
development of chest discomfort and increased lipid levels and
make dietary changes accordingly.

c) Schedule a myocardial perfusion imaging study to
determine the extent of myocardial damage and ischemia.

d) Screen the patient and family members for familial
hyperlipidemias and begin treatment of those family members
with hyperlipidemia.

Acknowledgment

All figures are reproduced with the expressed consent of the
first author. All patient data is redacted for patient privacy.

References

1. Inflammation and Heart Disease, Fleming Unified Theory of Vascular
Disease TX 7-451-244.


Circulation 139: e10820-e1143.

are Statins and PCSK9-Inhibitors? Scholarly journal of Food &

5. Ravnskov U, Diamond DM, Hama R, Tomohito Hamazaki, Björn
Hammarskjöld, et al. (2016) Lack of an association or an inverse


